Traditionally, tests have been metered that way because of costs (expensive reagents, preparation, processing) or side effects (radiation from scans). But the

Traditionally, tests have been metered that way because of costs (expensive reagents, preparation, processing) or side effects (radiation from scans). But the actual relevant equation is {cost of testing} vs {cost of delayed treatment} If the cost of testing, in economic and health senses, decreases while the cost of delayed treatment holds constant, a different mass deployment optimal point is created. Thankfully broader proactive testing is also in insurance companies' financial interests, given the high costs of late stage cancer treatment.